MENU
PFE
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

Pfizer (PFE) DIvidends Date & History

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion... Show more

A.I.Advisor
published Dividends

PFE is expected to pay dividends on December 07, 2026

Pfizer PFE Stock Dividends
A quarterly dividend of $0.43 per share will be paid with a record date of December 07, 2026, and an ex-dividend date of November 06, 2026. The last dividend of $0.43 was paid on September 01. Read more...
A.I.Advisor
Nov 02, 2026

Pfizer (PFE) Dividend Analysis: Can Its 7% Yield Keep Paying?

Key Takeaways

  • Pfizer (PFE) pays a quarterly dividend of $0.43 per share, or $1.72 annually, for a yield of roughly 6.9%.
  • The company has raised its dividend for 15–16 consecutive years, although the most recent increase stalled at $0.43 per share.
  • The trailing payout ratio on reported earnings is elevated, but cash-flow and forward-earnings coverage look far more comfortable.
  • Management has publicly committed to maintaining, and eventually growing, the dividend through its loss-of-exclusivity period.
  • The yield is well above the healthcare sector average, positioning Pfizer as an income-oriented holding rather than a classic growth stock.

Dividend Overview

Pfizer Inc. is a global biopharmaceutical company headquartered in New York. As a mature, cash-generative drugmaker, it operates a straightforward, shareholder-friendly dividend policy, paying a quarterly dividend of $0.43 per share, or $1.72 on an annualized basis. Based on recent trading levels, that equates to a dividend yield near 6.9% — far above the broader market and the healthcare sector average.

With a yield approaching 7%, Pfizer is best characterized as a high-yield dividend stock rather than a fast-growing dividend raiser. Payments are made every three months, providing steady, predictable income. The most recent ex-dividend date was July 24, 2026, with payment made September 1, 2026; the next ex-dividend date is November 6, 2026, with payment scheduled for December 7, 2026. Investors should own shares before the ex-dividend date to qualify for the upcoming distribution.

Dividend History and Growth

Pfizer has a long track record of returning capital to shareholders, having paid dividends for roughly four decades. The company increased its quarterly payout every year for more than a decade, lifting it from about $0.18 per share in 2010 to $0.43 by early 2025, with the annual step-up historically landing on the January payment.

That pattern has recently paused. The January 2026 payment held at $0.43, matching the prior four quarters instead of rising, and subsequent 2026 declarations have remained at the same rate. As a result, Pfizer's streak of consecutive annual increases has effectively stalled at 15–16 years while the payout itself remains intact. Management has framed this as a temporary freeze, stating that the dividend will be maintained and, after the current loss-of-exclusivity (LOE) period passes, will resume growing.

Dividend Sustainability and Payout Ratio

Assessing Pfizer's dividend requires looking at more than one metric. On trailing reported earnings, the payout ratio appears elevated at roughly 131%, a figure distorted by one-time accounting charges. On a cash-flow basis, however, coverage is far healthier, with the dividend consuming roughly 39% of operating cash flow. Forward estimates also point to a more comfortable payout ratio in the 57%–60% range.

This view is supported by management's guidance for 2026 adjusted diluted earnings per share (EPS) of $2.80 to $3.00 against a run-rate annual payout of $1.72. Management has also suspended share buybacks to prioritize balance-sheet strength, with leverage (the ratio of debt to earnings) near 2.7 times. In short, the dividend appears covered by adjusted earnings and free cash flow, though the elevated trailing earnings ratio and a paused growth streak warrant ongoing monitoring.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical group, Pfizer's dividend stands out as one of the highest. Rivals such as MRK (Merck) and BMY (Bristol-Myers Squibb) have continued raising their payouts, while Pfizer's increase has stalled. Even so, Pfizer's yield of roughly 6.9% is well above the healthcare sector average of around 1.5% to 2.8% and above the typical yield for large pharmaceutical peers.

By comparison, diversified healthcare names such as JNJ (Johnson & Johnson) and ABBV (AbbVie) offer yields in the low-to-mid single digits. In effect, Pfizer trades as a higher-yield, lower-growth income name, compensating investors for near-term revenue headwinds from patent expirations and declining COVID-19 product sales.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For income-focused research, the screener can help identify dividend stocks, high-yield names, and breakout candidates more efficiently than manual screening. Explore the AI Screener to refine your own list of dividend-paying opportunities.

Is This Stock Attractive for Dividend Investors?

Pfizer is likely to appeal primarily to income-focused investors seeking a high, predictable quarterly payout that currently exceeds 6%. The near-7% yield and management's public commitment to defending the dividend make it a candidate for those who prioritize current income over rapid payout growth. Long-term, value-oriented investors may also find the valuation and yield attractive relative to the broader pharmaceutical sector.

At the same time, the paused dividend streak and elevated trailing payout ratio may give dividend growth investors pause. Those who specifically target companies with rising payouts each year may prefer peers with more consistent recent increases. The key considerations are Pfizer's ability to maintain free cash flow through its loss-of-exclusivity period and whether adjusted earnings continue to comfortably cover the $1.72 annual payout. Overall, Pfizer presents a high-yield income profile with a maintained but currently frozen dividend, rather than an aggressive dividend-growth story.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of vaccines and injectable biologic medicines

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
66 Hudson Boulevard East
Phone
+1 212 733-2323
Employees
75000
Web
https://www.pfizer.com